The Latest Analyst Ratings For Ligand Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have shown a positive shift in sentiment towards Ligand Pharmaceuticals (NASDAQ:LGND) with recent ratings indicating a bullish outlook. The average 12-month price target has increased by 2.48% to $132.88. Despite positive revenue growth, the company faces challenges with profitability and financial returns.
October 03, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a positive shift in sentiment towards Ligand Pharmaceuticals with recent ratings indicating a bullish outlook. The average 12-month price target has increased by 2.48% to $132.88. Despite positive revenue growth, the company faces challenges with profitability and financial returns.
The article highlights a positive shift in analyst sentiment towards Ligand Pharmaceuticals, with an increase in the average price target. This suggests a bullish outlook in the short term. However, the company faces challenges with profitability and financial returns, which may temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100